PeptideStack
5.2kquestions
20kanswers
220users

Semaglutide or tirzepatide for a first course — what does the evidence support?

Asked 18 Jul 2025Modified 12 months agoViewed 17k times
28

I have read the medicinal chemistry paper and the pharmacology paper, which helped and did not finish the job.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

What does each option buy me, and what does it cost me?

semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questionsclinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
shareeditfollowflag
DW
askedDr_Elias_Weiss46k3818 Jul 2025
5Worth adding that the method section is where the answer usually is. – plunger_stop 2 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 17k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.